Stifel Reiterates Buy Rating on Crinetics (CRNX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
- Stocks, bonds edge up ahead of 'formidable' week for risk
Crinetics (CRNX) PT Raised to $80 at Morgan Stanley
January 5, 2026 1:44 PM ESTMorgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $80.00 (from $77.00) while maintaining a Overweight rating.
The analyst comments "We see atumelnant data continuing to demonstrate potential best-in-class efficacy, with no hepatic transaminase AEs. Nearterm, we expect investor... More



